

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC02200

315977

Licensee

1. Progress West Healthcare Center

2. 2 Progress Point Parkway
O'Fallon, MO 63368

3. License number 24-32642-01

4. Expiration date March 31, 2017

5. Docket No. 030-37397
Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300
- D. Any byproduct material permitted by 10 CFR 31.11

- A. Any
- B. Any
- C. Any
- D. Prepackaged Kits

- A. As needed
- B. As needed
- C. As needed, not to exceed 300 millicuries of iodine-131
- D. 100 millicuries

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 2 Progress Point Parkway, O'Fallon, Missouri.
- 11. The Radiation Safety Officer for this license is Mark Beanblossom.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-32642-01

Docket or Reference Number

030-37397


12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
William W. Baber, M.D.	10 CFR 35.100, 35.200 and 35.300.
Gene L. Davis, M.D.	10 CFR 35.100, 35.200 and 35.300.
John T. Engles, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Deborah Timmons Wadsworth, M.D.	10 CFR 35.100 and 35.200.
Dale M. Fletcher, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Christopher O. Thornton, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Walter G. Holloman, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Amy A. Mosher, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
John H. Niemeyer, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Robert F. Scheible, M.D.	10 CFR 35.100, 35.200 and 35.300.
Steven L. Solomon, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Geoffrey S. Hamill, M.D., Ph.D.	10 CFR 35.100 and 35.200.
Floyd E. Scales, M.D.	10 CFR 35.100 and 35.200.
Lisa M. Oakley, M.D.	10 CFR 35.100, 35.200 and 35.300.
Linda King Proctor, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Douglas J. Curry, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-32642-01Docket or Reference Number
030-37397

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 24, 2007, and,
- B. Facsimiles received February 14, 2007 and February 21, 2007.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 12 2007

By

Colleen Carol Casey
Colleen Carol Casey
Materials Licensing Branch
Region III